The ability of transforming growth factor-b (TGF-b) to modulate various effects on distinct cell lineages has been a central feature of its multi-faceted nature. The purpose of this study was to access the effects of deletion of a key TGF-b signal transducer, Smad3, on MAPK activation and v-Ras Ha -transformation of primary mouse embryonic fibroblasts (MEFs). We observe reduced TGF-b1 and v-ras Ha mediated activation of the JNK and ERK MAPK pathway upon ablation of Smad3. Further, Smad3-deficient MEFs demonstrate resistance to v-ras Ha -induced transformation while the absence of Smad3 results in increased inhibition of farnesyl transferase activity. Taken together, these observations demonstrate that the absence of Smad3 protects fibroblasts from oncogenic transformation by (i) augmenting farnesyl transferase inhibition and (ii) suppressing the Ras-JNK MAPK pathway. These results provide new insights into the molecular mechanisms involved in v-Ras Ha oncogene-induced mesenchymal phenotypic transformation.
Introduction
The most significant discovery in the field of cellular transformation was the identification of oncogenes and tumor suppressors, providing attractive targets for designing therapeutic as well as diagnostic strategies in oncology. The Transforming Growth Factor-b superfamily (TGF-bs) (Roberts et al., 1980) , includes more than 42 members including the TGF-bs, Nodals, Activins, Bone Morphogenic Proteins, Myostatin and Anti-Muellerian hormone among the others (Massague and Gomis, 2006) . TGF-b signaling universally regulates myriad cellular growth, development and physiological processes. Therefore, mutations in the TGF-b signaling pathway are commonly seen in many genetic disorders and diseases especially cancer (Blobe et al., 2000) . The precise role of TGF-b in malignancy has remained perplexing due to its multiple, and sometimes opposite, effects on specific cellular context. TGF-b has been shown to inhibit normal epithelial proliferation and primary tumors, but promote the metastatic phenotypes (Roberts and Wakefield, 2003) .
Both Smad3 and JNK have been shown to positively regulate TGF-b1 expression via an autocrine feedback loop through the AP1 sites in the TGF-b1 promoter (Kim et al., 1990; Ventura et al., 2004) . TGF-bs signal through the serine-threonine heterodimeric receptors, ALKs (Massague, 1992; ten Dijke et al., 1994) , via the canonical cytoplasmic intermediates, the Smads and a non-canonical signaling, termed 'Lateral Signaling', involving direct or indirect recruitment of the MAPKs, PI3K and PP2A among others that together mediate key biological outcomes (Byfield and Roberts, 2004) . This cytoplasmic crosstalk between the Smads and MAPK has also been widely investigated and the ability of the ERK to mediate linker phosphorylation of Smad3 has been well established (Hayashida et al., 2003; Matsuura et al., 2005) , while the reciprocal ability of Smads to mediate the activation of MAPK (ERK and JNK) has also been demonstrated . A recent report highlights the linker-phosphorylation of Smad3 and JNK MAPK activation as key steps in colorectal cancer progression Sekimoto et al., 2007) . The purpose of this study was to examine the consequence of loss of TGF-b-dependent Smad3 signaling on JNK MAPK activity and transformation potential of v-Ras Ha on mouse embryonic fibroblasts (MEFs).
Results and discussion

TGF-b signaling via the MAPK is perturbed by absence of Smad3
We first asked if TGF-b signaling via Smad3 regulate levels of JNK phosphorylation. To address this, we co-expressed JNK1 along with a constitutively activated Alk5 receptor (CA-ALK5) in Cos7 cells. Minimal JNK phosphorylation was observed in the presence of endogenous Smad3, (Figure 1a ; lane 1) while a dose-dependent increase in JNK1 phosphorylation was observed when Smad3 was coexpressed along with CA-ALK5 (Figure 1a ; lane 4). These observations suggest that TGF-b enhances JNK1 phosphorylation in a Smad3-dependent manner.
Next, we explored this phenomenon more directly using a genetically tractable system using primary MEFs derived from S3WT and S3KO mutant mice. A dramatically reduced level of phospho-JNK was seen in TGF-b-treated S3KO cells compared to S3WT MEFs (Figure 1b Immunoblotting was performed with 20-50 mg of samples using Tris-Glycine gels (Invitrogen, Carlsbad, CA, USA), 0.2 mm Nitrocellulose (Amersham, Piscataway, NJ, USA) and incubated with primary antibodies against Phospho-JNK, Phospho-ERK, total JNK and total ERK (all Cell Signaling, Danvers, MA, USA) followed by anti-rabbit HRP secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and chemiluminescence (ECL Plus, Pierce Biotechnology Inc., Rockford, IL, USA) was detected by films (Kodak MR, Sigma-Aldrich, St Louis, MO, USA) or digital imager (AlphaInotech, San Leandro, CA, USA). Primary mouse embryonic fibroblasts (b-d) were isolated from wild-type (S3WT), Heterozygote (S3Het) and knockout (S3KO) embryos between 12 and 16 days of gestation (Piek et al., 2001) , propagated in Dulbecco's-modified Eagle's medium (DMEM) (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) (Hyclone) and 1% penicillin-streptomycin (Gibco, Grand Island, NY, USA), grown to confluence and used between 2 and7 passages for all assays. Blots are representative of atleast three independent experiments.
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total ERK levels were similar in both cell lines (Figure 1b) . To evaluate the specificity of TGF-b/Smad3 in MAPK activation, we independently tested the effects of two known MAPK-activating cytokines; TNFa and EGF that do not involve Alk5 (TGFb RI). While loss of Smad3 resulted in a reduced TGF-b-mediated JNK phosphorylation, a similar effect was not observed with either TNF-a or EGF and was independent of Alk5 ( Figures 1c and d ).
These results demonstrate that TGF-b-mediated activation of MAPK signaling alone requires intact Smad3 function.
Smad3 KO MEFs demonstrate decreased JNK activation following v-ras Ha overexpression Next, we examined the physiological relevance of Smad3 dependency in the TGF-b-mediated JNK/ERK phosphorylation. The interplay between TGF-b and Ras pathway in activating the MAPK has been investigated and has been shown to vary dramatically depending on growth conditions and additional factors present in the milieu (Yue and Mulder, 2001 ). TGF-b is known to differentially modulate the oncogenic properties of Ras, either synergistically (Oft et al., 1996; Bost et al., 1999; Lehmann et al., 2000; Park et al., 2000; Santibanez et al., 2003) or antagonistically (Filmus et al., 1992; Kretzschmar et al., 1999; Saha et al., 2001; Santibanez et al., 2002; Kennedy et al., 2003; Vijayachandra et al., 2003; Wisdom et al., 2005) , suggesting that the presence of additional factors and signaling crosstalk are key determinants of the eventual malignant outcome. Therefore, we asked if the status of Smad3 expression, in the context of an oncogenic ras signal, regulates the activity of JNK and ERK. Phospho-JNK levels were significantly increased upon v-ras Ha infection of S3WT MEFs compared to basal levels, while in contrast, we observed a decreased JNK activation in S3KO cells (Figure 2) . Moreover, treatment of v-ras Ha -infected cells with TGF-b1 resulted in further increase of activated phospho-JNK levels in the S3WT MEFs whereas no similar induction in JNK phosphorylation was detected in TGF-b1-treated v-ras Ha -infected S3KO MEFs. We also observed a similar reduction in phospho-ERK activation in v-ras Ha -infected S3KO MEFs upon TGF-b1 treatment (Figure 2 ), although interestingly, activation of p38 MAPK did not seem to be significantly affected (data not shown).
Smad3 KO MEFs are resistant to v-ras
Ha oncogenic transformation Next, we evaluated the functional consequences of the reduction in JNK/ERK signaling in v-ras Ha -infected MEFs and phenotypic transformation. In response to v-ras Ha infection, the S3WT fibroblasts demonstrate an elongated transformed phenotype with low multiplicity of infection while at higher multiplicity of infection we observed the formation of characteristic colonies representing the loss of contact inhibition and phenotypic oncogenic transformation. Strikingly, the S3KO MEFs treated at similar multiplicity of infections of v-ras Ha do not show morphological changes or monolayer growth characteristics consistent of transformed cells (Figure 3 ). These observations are consistent with previous demonstrations that JNK deficient MEFs are resistant to phenotypic transformation with the v-ras Ha oncogene (Kennedy et al., 2003) .
Absence of Smad3 results in increased farnesyl transferase inhibition activity
Prenylation of Ras is necessary for its membrane associated localization and critical for its biological Ha replication-defective ecotropic retrovirus was a kind gift from Adam Glick, NCI and was prepared using c2 producer cells (Roop et al., 1986) . Culture supernatants with v-ras Ha retrovirus titers of routinely 1 Â 10 7 virusml À1 were use to infect MEFs on day 3 of culturing at multiplicity of infections ranging from 0.1 to 10 in medium containing 4 mgml À1 Polybrene (Sigma-Aldrich). Cells were incubated in routine culture conditions (5% CO 2 and 30% O 2 ) for 2-3 weeks, medium replenished every 3 days and culture dishes were photographed for colony formation and harvested for immunoblotting for Phospho-JNK, Phospho-ERK, Total JNK and Total ERK (All from Cell Signaling) and Smad 2/3 (BD Transduction Laboratories, San Jose, CA, USA) analysis at different time points as described previously. Blots are representative of atleast three independent experiments. Smad3 deficiency protects MEFs from transformation PR Arany et al function (Kato et al., 1992) . Ras can be prenylated by either Farnesyl transferases or geranylgeranyl transferases. Farnesylation of H-Ras has been shown to be crucial for its oncogenic activities while farnesyl transferase inhibition seems to be protective (Prendergast et al., 1994) . Geranylgeranylation has also been shown to induce similar phenotypic changes characteristic of transformation (Cox et al., 1994) , but differs in its ability to mediate the pro-apoptotic effects in transformed cells (Brassard et al., 2002) as well as inhibit growth of non-transformed cells .
Since our results suggested that Smad3 ablation results in inhibition of v-ras Ha induced transformation, we next asked whether farnesyl transferase inhibition contributes to the observed resistance of the MEFs to transformation by oncogenic v-ras Ha . We treated S3WT, S3Het and S3KO MEFs with a commercially available farnesyl transferase inhibitor (FPTI-3) and monitored the levels of Prelamin A, a surrogate downstream marker of farnesyl transferase inhibition (Fong et al., 2006) . Elevated levels of Prelamin A were observed in vRas Ha -transformed S3Het and S3KO MEFs indicative of increased inhibition of farensyl transferase activity in these cells (Figure 4 ; lanes 4-9) compared to similarly treated S3WTs (Figure 4; lanes 1-3) .
Conclusion
The primary step in a malignancy is the ability of the normal cell to undergo 'transformation' and while most Smad3 deficiency protects MEFs from transformation PR Arany et al research has been focused on the role of various oncogenes in epithelial cell transformation, much less is known about their mediating mesenchymal cellular behavior. TGF-b is primarily involved in many facets of epithelial and mesenchymal cellular behavior and insights into heterotypic TGF-b signaling by mesenchymal fibroblast modulating the malignant phenotype of the overlying epithelium has further complicated its role in vivo (Bhowmick et al., 2004; Egeblad et al., 2005; Radisky et al., 2007) . A recent report using a small molecule kinase inhibitor of Alk5 (TGF-b RI) inhibiting the TGF-b pathway demonstrated efficacy in blocking the mesenchymal tumors while promoting the epithelial tumors in a transgenic mouse model (Laping et al., 2007) further emphasizing the multi-faceted nature of TGF-b in mediating biological outcomes based on cell lineages and tissue context as we have also observed in wound healing (Arany et al., 2006) . Farnesyl transferase inhibition can result in differential downstream Ras and Non-Ras target gene expression, especially on Rho GTPases, that mediate TGF-b signaling and in turn could alter the cytoskeleton contributing to the transformed phenotype and anchorage-independent growth (Atfi et al., 1997; Lebowitz and Prendergast, 1998; Bhowmick et al., 2001; Prendergast, 2001) In this study, we use primary MEFs from S3WT and KO mice and Ras oncogene to analyse the role of the Smad3 in the TGF-b signaling pathway and in mediating malignant transformation. We conclude from our observations that Smad3 is critical for v-ras Ha -mediated transformation in MEFs and acts via Ras Farnesylation and JNK signaling pathway (see Supplementary Figure  online) . Further studies are required to dissect the precise role of the various molecular and cellular aspects of v-ras Ha transformation.
